Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag in Pediatric Fanconi Anemia
NCT06045052Phase 2Completed
- Start
- Dec 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in Fanconi anemia (FA). Primary endpoint: Efficacy of eltrombopag on hematopoiesis at 6 months. Started Dec 2020; status: completed.
02
Drugs
eltrombopag
03
Conditions
Fanconi anemia (FA)
Beyond the preview
Go deeper on NCT06045052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06045052.